AMD
Advanced Micro Devices, Inc.
AMD's fundamentals are strong: revenue grew 42% and its operating margin rose 9 points to 18%. At 127x earnings, it's trading above its usual 113x. Analysts expect that strong growth to continue, though they disagree widely on how much.
SURG
SurgePays, Inc.
There isn't enough reported data to score SURG yet.
AMD Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
AMD's revenue, profitability, cash flow and balance sheet are all currently strong.
SURG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Strong |
SURG's revenue and balance sheet are currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow.
AMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 39x | $585 | — |
| Cheap | 40x | $182 | -69% |
| Fair | 112x | $514 | -12% |
| Current | 127x | $585 | — |
| Expensive | 206x | $947 | +62% |
Historical ranges are pointers, not guarantees.
AMD's PE is in its fair range at 127x. If earnings grow as analysts expect, today's price would be 39x next year's earnings, in its cheap range.
SURG PE Valuation
SURG has no meaningful PE right now: it lost money over the past year.
AMD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Broad | |
| Low |
AMD has the edge over SURG on the outlook, with more favorable revenue expectations.
SURG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect SURG's losses to shrink, with revenue holding steady.
AMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $15.05 | +227% |
| Q3 2026 | $4.60 | +127% |
| Q2 2026 | $3.89 | +122% |
| Q1 2026 | $3.05 | +123% |
| Q4 2025 | $2.65 | +165% |
| Q3 2025 | $2.03 | +81% |
| Q2 2025 | $1.75 | +111% |
| Q1 2025 | $1.37 | +99% |
| Q4 2024 | $1.00 | +89% |
AMD has the edge over SURG on earnings quality, reporting a profit while its opponent remains loss making.
SURG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.52 | +$1.02 |
| Q1 2026 | -$1.93 | +$0.91 |
| Q4 2025 | -$1.80 | +$0.59 |
| Q3 2025 | -$2.19 | -$1.05 |
| Q2 2025 | -$2.54 | -3275% |
| Q1 2025 | -$2.84 | -349% |
| Q4 2024 | -$2.39 | -273% |
| Q3 2024 | -$1.14 | -179% |
SURG is still losing money, but far less than before: $1.52 per share over the past year, against $5.50 at its worst in early 2021.
AMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13.4B | +45% |
| Q2 2026 | $11.5B | +50% |
| Q1 2026 | $10.3B | +38% |
| Q4 2025 | $10.3B | +34% |
| Q3 2025 | $9.2B | +36% |
| Q2 2025 | $7.7B | +32% |
| Q1 2025 | $7.4B | +36% |
| Q4 2024 | $7.7B | +24% |
AMD has the edge over SURG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +7.4 points |
| Q2 2026 | 17% | +19 points |
| Q1 2026 | 14% | +3.6 points |
| Q4 2025 | 17% | +5.7 points |
| Q3 2025 | 14% | +3.1 points |
| Q2 2025 | -1.7% | -6.4 points |
| Q1 2025 | 11% | +10 points |
| Q4 2024 | 11% | +5.8 points |
AMD's operating margin was 21% last quarter, up 7.4 points from the same quarter a year ago.
SURG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $16.2M | +41% |
| Q1 2026 | $16M | +51% |
| Q4 2025 | $16.2M | +69% |
| Q3 2025 | $18.7M | +292% |
| Q2 2025 | $11.5M | -24% |
| Q1 2025 | $10.6M | -66% |
| Q4 2024 | $9.6M | -70% |
| Q3 2024 | $4.8M | -86% |
SURG's revenue is recovering but still below its 2022 peak: $16M last quarter, up 41% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 21% | +80 points |
| Q1 2026 | -70% | +1.6 points |
| Q4 2025 | -79% | +113 points |
| Q3 2025 | -37% | +262 points |
| Q2 2025 | -59% | +13 points |
| Q1 2025 | -72% | -77 points |
| Q4 2024 | -192% | -194 points |
| Q3 2024 | -299% | -320 points |
SURG has the edge over AMD on profitability, with a higher operating margin.
AMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $554M | -71% |
| Q2 2026 | $1.6B | -9.9% |
| Q1 2026 | $2.6B | +253% |
| Q4 2025 | $2.4B | +118% |
| Q3 2025 | $1.9B | +283% |
| Q2 2025 | $1.7B | +294% |
| Q1 2025 | $727M | +92% |
| Q4 2024 | $1.1B | +351% |
AMD has the stronger cash trend. Its trailing FCF is up 128% versus its history, compared with SURG at down 63%.
SURG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.6M | +$3.5M |
| Q1 2026 | -$4.6M | +$2.4M |
| Q3 2025 | -$4.6M | +$8.7M |
| Q2 2025 | -$6.1M | -$2M |
| Q1 2025 | -$7M | -272% |
| Q4 2022 | $4.7M | +$12.9M |
| Q3 2022 | -$801.2K | +$1.5M |
| Q2 2022 | $175.5K | +$1.6M |
SURG has burned cash in almost every quarter: −$18M over the past year, against −$20M the year before.
AMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +2M shares |
| 1 year | +1.2% | +20M shares |
| 3 years | +2% | +32M shares |
| 5 years | +35% | +431M shares |
| Available history | +40% | +473M shares |
AMD has the edge over SURG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $221M |
| Q4 2025 | — |
| Q3 2025 | $89M |
| Q2 2025 | $478M |
| Q1 2025 | $749M |
| Q4 2024 | $256M |
AMD has spent almost nothing on buybacks in the past year.
SURG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.4% | +2.2M shares |
| 1 year | +29% | +5.9M shares |
| 3 years | +109% | +13.5M shares |
| 5 years | +1122% | +23.8M shares |
SURG has 26M diluted shares, up 29% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
AMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2020 | -1.0x | Net Cash |
| Q1 2020 | -0.8x | Net Cash |
| Q4 2019 | -1.2x | Net Cash |
AMD has more cash than debt.
SURG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -2.2x | Net Cash |
| Q4 2023 | -0.5x | Net Cash |
| Q3 2023 | -0.3x | Net Cash |
| Q2 2023 | 0.0x | Very low |
| Q1 2023 | -0.3x | Net Cash |
| Q4 2022 | 0.4x | Very low |
SURG has more cash than debt.
AMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.3 | Neutral |
| Stochastic | 41.4 | Neutral |
AMD's weekly RSI is 59 (neutral) and its Stochastic is 41 (neutral).
SURG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.5 | Neutral |
| Stochastic | 13.7 | Oversold |
SURG's weekly RSI is 32 (neutral) and its Stochastic is 14 (oversold).
AMD PE vs Technology Sector
| Metric | AMD | Sector median | Relative |
|---|---|---|---|
| PE | 127x | 28x | 357% above |
| PE % | 61 | 35 | 26 pts above |
AMD is trading at 127x earnings, a 357% premium to the Technology sector's median of 28x.
SURG PE vs Technology Sector
| Metric | SURG | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
SURG has no meaningful PE right now: it lost money over the past year.
AMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $557.2 | 5.1% above |
| 20 week MA | $525.9 | 11% above |
| 50 week MA | $389.7 | 50% above |
| 100 week MA | $266.9 | 119% above |
| 200 week MA | $199.6 | 193% above |
AMD has the edge over SURG on trend strength, trading above more of its moving averages.
SURG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.14 | 0% above |
| 20 week MA | $0.21 | 33% below |
| 50 week MA | $0.65 | 78% below |
| 100 week MA | $1.50 | 91% below |
| 200 week MA | $3.02 | 95% below |
SURG is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
AMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $46.2 | $91.8 | +99% |
| 2021 | $91.8 | $146.1 | +59% |
| 2022 | $146.1 | $64.5 | -56% |
| 2023 | $64.5 | $147.4 | +128% |
| 2024 | $147.4 | $125.2 | -15% |
| 2025 | $125.2 | $215.0 | +72% |
| 2026 YTD | $215.0 | $585.3 | +172% |
AMD has the edge over SURG on returns for 2026, with the stronger performance.
SURG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.8 | $6.00 | -59% |
| 2021 | $6.00 | $2.31 | -62% |
| 2022 | $2.31 | $6.29 | +172% |
| 2023 | $6.29 | $6.45 | +2.5% |
| 2024 | $6.45 | $1.83 | -72% |
| 2025 | $1.83 | $1.68 | -8.2% |
| 2026 YTD | $1.68 | $0.14 | -92% |
SURG's yearly returns have swung widely, from +172% in 2022 to −72% in 2024. It's down 92% so far in 2026.